^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OCV-501

    i
    Associations
    News

    Trials

    Company:
    Otsuka
    Drug class:
    Immunostimulant, Wilms tumor 1 antigen modulator
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients (NCT01440920)
    Phase 1
    Otsuka Pharmaceutical Co., Ltd.
    Completed
    Last update posted :
    03/08/2021
    Initiation :
    09/01/2011
    Primary completion :
    03/01/2013
    Completion :
    07/01/2013
    RARA • HLA-DRB1
    |
    HLA-DRB1*01:01
    |
    OCV-501